Main Conference: 28-30 April 2026 | Vienna, Austria
ATMP Development & Manufacturing
Lowering cell, gene and advanced therapy costs through automation and advanced analytics.
Go Beyond Theory on ATMP Commercialisation
The ATMP Development & Manufacturing track is a 3-day program focused on solving the biggest hurdles to commercialisation: such as the cost of goods and manufacturing complexities. This track provides actionable strategies from global leaders on how to automate manufacturing, enhance analytics, tackle CMC hurdles , and scale up the next generation of 'off-the-shelf' therapies
Session Spotlight: ATMP Development & Manufacturing
CASE STUDY: Bridging the Valley of Death - De-Risking ATMP Tech Transfer from Lab to GMP
Tuesday 28th April 2026 11:45am
Pablo Mancheño Corvo, Associate Scientific Director at Takeda
Real-world case study of a complex ATMP tech transfer from small-scale lab to larger-scale GMP site
Defining and locking down critical process parameters (CPPs) and material attributes early
Strategies for managing comparability with preclinical studies
Best practices for collaboration and knowledge management:
Accelerate timelines and de-risk path to clinic.
Track Themes: A Blueprint for Industrialising ATMPS
Solving the COGS Crisis
Hear real-world case studies on decreasing manufacturing costs and reducing plasmid dependency.
De-Risking the Journey to the Clinic
Master phase-appropriate CMC strategies and de-risk your tech transfer from the lab to GMP.
Automation & Allogeneic Frontiers
See how leaders are implementing closed, automated systems to scale 'off-the-shelf' allogeneic therapies.
The Future of Delivery
Go beyond viral vectors and explore the manufacturing and CMC challenges for in vivo and LNP-based delivery.
Meet the Advanced Therapy Experts
Get actionable strategies on ATMP analytics, tech transfer, and scaling from the pioneers turning advanced therapies into commercial realities.
Explore the full ATMP Development & Manufacturing Agenda
ATMP Development & Manufacturing: Q&A & Expert Insights
How can cell and gene therapy developers reduce Cost of Goods (COGS)?
Addressing the "COGS Crisis" requires radical changes in manufacturing strategy, such as optimising the "Make vs. Buy" decision and selecting the right CDMO partnership. Technical solutions include implementing closed, automated systems to reduce labour costs and employing process intensification to drive down the cost per dose for commercial viability.
What is cell-free synthesis for AAV manufacturing?
Cell-free synthesis is an enzymatic system that bypasses living cells entirely to assemble AAV vectors. This technology offers a potential step-change in speed and scalability, producing high-quality vectors in hours rather than weeks and eliminating the biological variability associated with traditional cell-based production.
Why is the transition to closed, automated systems critical for cell therapy?
Automating cell therapy manufacturing (e.g., using robotic isolators) removes human error and ensures sterility, which is essential for regulatory compliance. Closed systems enable the scalable production of both autologous and allogeneic therapies by maintaining a controlled environment from "vein-to-vein" and simplifying the validation of the manufacturing process.
What are the key challenges in LNP manufacturing for in vivo delivery?
Manufacturing Lipid Nanoparticles (LNPs) requires precise control over Critical Process Parameters (CPPs) to ensure consistent particle size and efficient encapsulation of the payload (e.g., mRNA or gene-editing tools). Scaling these processes from the lab to GMP requires robust strategies to maintain particle attributes and stability for effective in vivo delivery.